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Introduction: Renal cell carcinoma associated with Xp11.2 translocations is frequently reported in children, but
adult-onset is rare. Here, the case of an adult male who developed a renal cell carcinoma associated with Xp11.2
translocations is presented.
Case presentation: A 38-year-old Asian man presented with left back pain and macroscopic hematuria. Computed
tomography revealed a left renal tumor (T3N2M0), and a left radical nephrectomy was performed.
Hematoxylin-eosin staining revealed papillary architecture and clear or eosinophilic cytoplasm, and the diagnosis of
renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion was made by the
immunohistochemical determination of transcription factor E3 protein. In spite of adjuvant therapy with
α-interferon, a recurrent tumor was found in his left lung by computed tomography three months after the
nephrectomy. Interleukin-2, tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors showed no
effect on tumor progression.
Conclusions: Renal cell carcinomas associated with Xp11.2 translocations have an aggressive clinical course in
adults. Strict diagnosis using the immunohistochemistry of transcription factor E3 protein is important to predict
the prognosis of such patients and new strategies need to be determined to treat patients with these tumorsIntroduction
Renal cell carcinoma (RCC) associated with Xp11.2
translocations has recently been discovered and inte-
grated into the World Health Organization classification
[1]. This type of tumor frequently occurs in children,
but adult-onset cases have only lately been reported
[2,3]. There are few such reports, and little is known
about the clinical course and biological characteristics of
this tumor. A case of adult-onset RCC associated with
p11.2 translocations is here reported.Case presentation
A 38-year-old Asian man presented with macroscopic
hematuria and left back pain. He underwent computed
tomography of his abdomen and a large enhancing left* Correspondence: amorii@med.u-toyama.ac.jp
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reproduction in any medium, provided the orrenal mass and renal hilar lymph node swelling were
noted (Figure 1). The tumor was located in the middle-
inferior portion of his left kidney. He had no previous
history of chemotherapy. All his blood test results were
unremarkable. A radical left nephrectomy was per-
formed and the lymph nodes were simultaneously
removed.
An ill-demarcated tumor measuring 6 × 6 × 7.5cm was
observed in the middle-inferior pole of his left kidney.
The cut surface was yellow or white in color. There was
hemorrhage and necrosis present.
On microscopy, the tumor consisted of a combined
epithelial and sarcomatous component. The epithelial
component comprised neoplastic cells with clear or eo-
sinophilic cytoplasm (Figure 2a). Regarding the architec-
tural aspects, the epithelial component had a solid
growth pattern or a papillary growth pattern with deli-
cate fibrovascular cores. The neoplastic epithelial cells
had enlarged nuclei with an irregular nuclear membrane
and distinct nucleoli. This nuclear atypia correspondedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Abdominal enhanced computed tomography scan at
diagnosis. (a) A tumor of the left kidney measuring 7.2 × 6.5cm
(arrow); (b) lymph node swelling in the renal hilar region (arrow).
Figure 2 Histological finding for left renal tumor.
(a) Hematoxilin and eosin staining: the cytoplasm was clear or
eosinophilic, and tumor cells proliferated with a papillary
architecture or solid pattern; (b) transcription factor E3
immunohistochemical labeling of the left renal tumor: nuclei of
many tumorous cells were diffusely positive for transcription factor
E3.
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sisted of spindle cells with fibroconnective stroma. The
neoplastic sarcomatous cells had enlarged irregular nu-
clei with distinct nucleoli. This nuclear atypia corre-
sponded to Fuhrman Grade 3 to 4. These findings were
consistent with sarcomatoid change.
Immunohistochemistry revealed that the nuclei of many
tumor cells were positive for transcription factor E3
(TFE3) (Figure 2b). In addition, the neoplastic epithelial
cells were diffusely positive for alpha-methylacyl-coenzyme
A racemase, CAM5.2 and EMA, and focally positive for
cluster of differentiation 10 and vimentin. The neoplastic
sarcomatous cells were focally positive for alpha-
methylacyl-coenzyme A racemase, EMA and vimentin.
The tumor cells, however, were negative for cytokeratin 7,
Melan A and human melanoma black-45. Therefore, the
tumor was finally diagnosed as RCC associated with
Xp11.2 translocation/TFE3 gene fusion. Renal vein involve-
ment was demonstrated, but lymph node metastasis and
distant metastasis were absent. Accordingly, the tumor was
classified as pT2pN0M0, Stage II.Alpha-interferon was administered as adjuvant therapy
after the surgery. A recurrent mass was found in his left
lung by computed tomography three months after sur-
gery, in spite of the adjuvant therapy. The tumor enlarged
despite treatment with interleukin-2. Tyrosine kinase inhi-
bitors sunitinib and sorafenib and the mammalian target
of rapamycin inhibitor everolimus were sequentially admi-
nistered, but the tumor showed no response. Metastatic
tumors developed in our patient’s brain, liver and bone
and he died 16 months after the nephrectomy.
Discussion
RCC associated with Xp11.2 translocations accounts for
approximately 5% to 20% of RCCs in pediatric and ado-
lescent patients, but it is much less common in adults
[4]. Five patterns of fusion with the TFE3 gene, with
APSL, PRCC, PSF, NonO and CLTC genes, have been
found [2,5]. There is little data concerning the mechan-
ism and factors associated with this tumor.
These tumors have an aggressive clinical course in
adults [5]. They show poor prognosis, owing to the lack
of effective therapy apart from surgery. Moreover, many
patients already have local invasion and/or metastasis at
the time of diagnosis [4]. Argani et al. reported that 14
of 28 patients with adult-onset Xp11 translocation RCC
presented at stage IV, whereas metastatic carcinoma
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whom the lymph nodes were resected [2]. Meyer et al.
suggested that it was possible that translocation RCCs
develop when patients are young, but the tumors are not
detected until reaching an advanced stage [6].
Chemotherapy, including the molecularly-targeted drugs
α-interferon and interleukin-2 [3,6,7], is used to treat these
tumors but have no effect. Choueiri et al. reported the out-
come of 12 patients with RCC associated with Xp11.2
translocations undergoing anti-vascular endothelial growth
factor therapy, three of whom achieved a partial response.
They concluded that vascular endothelial growth factor-
targeted agents appeared to demonstrate some efficacy
for these patients [8]. Alpha-interferon, interleukin-2, sora-
fenib, sunitinib and everolimus were administered to our
patient, but tumor progression could not be suppressed.
The histological features that are useful in differentiat-
ing RCC associated with Xp11.2 translocations from
the other types of RCC include the combinations of
nested and papillary architecture, clear cytoplasm, and
extensive psammomatous calcifications. However, these
morphological features may overlap with other more
common types of RCC. The most distinctive immuno-
histochemical marker of RCC associated with Xp11.2
translocations is detectable nuclear staining for TFE3
protein. All TFE3 fusion proteins retain the C-terminal
portion of TFE3. The RCC in the current patient
showed papillary architecture and clear cytoplasm, and
the tumor was diagnosed by immunohistochemical find-
ings of TFE3 protein. Strict diagnosis using the immu-
nohistochemistry of TFE3 may increase the number of
cases of RCC associated with Xp11.2 translocations that
are reported.
Recently, Tsuda et al. [9] demonstrated that TFE3
increases Met protein expression in cellular cancer cell
lines, including in renal carcinoma. They revealed the re-
sponsiveness of an Xp11 translocation RCC cell line to a
Met inhibitor. Sagara et al. [7] reported the case of a pa-
tient with TFE3-renal carcinoma with strong expression
of pY1234/1235 hepatocyte growth factor receptor/Met.
The hepatocyte growth factor receptor/Met signaling
pathway stimulates cell proliferation and migration in
many cancers [10]. This could be a therapeutic target
and further investigations might discover new strategies
to treat patients with these tumors.
Conclusions
We present a case of an adult-onset RCC associated with
Xp11.2 translocations. These tumors have an aggressive
clinical course in adults, and there is no effective treat-
ment. Strict diagnosis using the immunohistochemistry
of TFE3 is important to predict the prognosis of such
patients and new strategies are needed to treat patients
with these tumors.Consent
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